Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials by Boutitie, Florent et al.
RESEARCH
Influenceofprecedinglengthofanticoagulanttreatmentand
initial presentation of venous thromboembolism on risk of
recurrence after stopping treatment: analysis of individual
participants’ data from seven trials
FlorentBoutitie,statisticalinvestigator,
1LaurentPinede,investigator,
2SamSchulman,professor,
3,4Giancarlo
Agnelli, professor,
5 Gary Raskob, professor,
6 Jim Julian, statistical investigator,
7 Jack Hirsh, professor
emeritus,
4 Clive Kearon, professor
4
ABSTRACT
ObjectiveTodeterminehowlengthofanticoagulationand
clinical presentation of venous thromboembolism
influence the risk of recurrence after anticoagulant
treatmentisstoppedandtoidentifytheshortestlengthof
anticoagulation that reduces the risk of recurrence to its
lowest level.
Design Pooled analysis of individual participants’ data
from seven randomised trials.
Setting Outpatient anticoagulant clinics in academic
centres.
Population 2925 men or women with a first venous
thromboembolism who did not have cancer and received
different durations of anticoagulant treatment.
Main outcome measure First recurrent venous
thromboembolism after stopping anticoagulant
treatment during up to 24 months of follow-up.
Results Recurrence was lower after isolated distal deep
veinthrombosisthanafterproximaldeepveinthrombosis
(hazardratio0.49,95%confidenceinterval0.34to0.71),
similarafterpulmonaryembolismandproximaldeepvein
thrombosis (1.19, 0.87 to 1.63), and lower after
thrombosisprovokedbyatemporaryriskfactorthanafter
unprovoked thrombosis (0.55, 0.41 to 0.74). Recurrence
was higher if anticoagulation was stopped at 1.0 or 1.
5monthscomparedwithat3monthsorlater(hazardratio
1.52, 1.14 to 2.02) and similar if treatment was stopped
at 3 months compared with at 6 months or later (1.19,
0.86 to 1.65). High rates of recurrence associated with
shorter durations of anticoagulation were confined to the
first 6 months after stopping treatment.
Conclusion Three months of treatment achieves a similar
risk of recurrent venous thromboembolism after stopping
anticoagulation to a longer course of treatment.
Unprovoked proximal deep vein thrombosis and
pulmonary embolism have a high risk of recurrence
whenever treatment is stopped.
INTRODUCTION
Venous thromboembolism, which encompasses deep
vein thrombosis and pulmonary embolism, is usually
treated with a short course of a parenteral heparin, fol-
lowed by a longer course of oral vitamin K antagonist
treatment.
1 The decision to continue anticoagulant
treatment beyond the first few months is based on the
treating physician’s perception of the benefits and
harmsofcontinuingtreatmentandonthepatient’spre-
ference.The benefitsand harmsassociatedwith differ-
ent lengths of vitamin K antagonist treatment have
been evaluated in several studies that randomly allo-
cated patients with venous thromboembolism to
receivedifferentlengthsoftreatment.Threeclearmes-
sages have emerged from the findings of these studies.
Firstly, in unselected patients with venous thrombo-
embolism, shortening the length of treatment from
three or six months to 1.0 or 1.5 months results in a
substantial increase in the frequency of recurrent
thromboembolism after anticoagulants are stopped.
2-4
Secondly, vitamin K antagonist treatment targeted to
aninternationalnormalisedratioof2.5isveryeffective
at preventing recurrent venous thromboembolism.
56
Thirdly, the risk of recurrent thromboembolism
increases after vitamin K antagonist treatment is
stopped.
2-47-9 However, the results of these individual
trials, and meta-analysis of summary data of their
findings,
10-14 have failed to answer many important
questions relating to the optimal length of vitamin K
antagonist treatment for venous thromboembolism.
The most important limitation of individual studies
that have evaluated the optimal length of vitamin K
antagonist treatment for venous thromboembolism is
that they only compared two lengths of treatment.
Consequently, although studies could identify which
of two lengths of treatment was superior, no study
was in a position to determine if the superior length
of treatment was also the optimal length of treatment;
perhaps a third length of treatment would result in
even better clinical outcomes. Another limitation of
individual studies is that they included insufficient
numbers of patients in subgroups to be able to deter-
mine if the main findings of each study applied to all
patients.Forexample,ifclinicalfeaturesidentifyasub-
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whohaveasubstantiallylowerriskofrecurrentthrom-
bosis after vitamin K antagonist treatment is stopped,
such patients might benefit from a shorter duration of
treatment.
Byincreasingthenumberofpatientsstudiedandthe
spectrum of lengths of treatment evaluated, and by
enabling time to event analyses and adjustment for
confounding variables (such as patients’ age and sex),
meta-analysis of individual patients’ data from several
trials has the potential to answer questions that indivi-
dual trials, and meta-analyses of aggregate data from
such trials, cannot answer.
15 For this reason, the
authors of seven studies that compared various length
of vitamin K antagonist treatment for venous throm-
boembolism pooled individual patients’ data from
their studies.
346-912 Our primary goal was to identify
the shortest length of treatment that reduced the risk
of recurrence to its lowest value after stopping treat-
ment, including in subgroups defined according to
the location of the initial venous thromboembolism
(for example, isolated distal deep vein thrombosis,
proximal deep vein thrombosis, pulmonary
embolism)
491617 and whether thrombosis was pro-
voked by a temporary risk factor or was unprovoked
(that is, no temporary risk factor or association with
cancer was present).
2-4918
METHODS
Description of original studies
The seven included studies enrolled adult men or
women with objectively confirmed deep vein throm-
bosis or pulmonary embolism who did not have
known cancer at diagnosis (some patients with cancer
were included in one study but excluded from this
analysis
3); treated patients with different lengths of
vitamin K antagonist treatment adjusted to achieve
an international normalised ratio of 2.0 to 3.0
36-912 or
2.0 to 2.85
4; prospectively followed patients after
anticoagulant treatment was stopped; and used objec-
tive testing to diagnose recurrent venous thromboem-
bolism (table 1). All studies included participants who
were randomly allocated to one of two lengths of
treatment. Two studies included two distinct popula-
tions of patients, each with its own randomised treat-
mentoptions(table 1).
89Inadditiontotherandomised
participants, one study included a concurrent cohort
who were treated for three months because they had
abnormal impedance plethysmography four weeks
after diagnosis of deep vein thrombosis.
3 One study
contributed patients to this analysis who were not
included in the initial publication because they had
yet to complete 12 months of follow-up.
8 Another
study contributed data on patients who stopped anti-
coagulants after 27 months that were not included in
the original publication.
6
We identify studies by their acronyms as follows:
Optimal Duration of Anticoagulation study
(ODAC),
3 Duree Optimale du Traitement Anti Vita-
mines K study (DOTAVK),
9 Duration of Anti-
coagulation study 1 (DURAC 1),
4 Long-term
AnticoagulationforFirstIdiopathicThrombosisstudy
(LAFIT),
6 Warfarin Optimal Duration Italian Deep
Vein Thrombosis study (WODIT DVT),
7 Warfarin
Optimal Duration Italian Pulmonary Embolism
study (WODIT PE),
8 and Short term Oral anti-
coagulation for a First Acute Secondary Thrombosis
study (SOFAST)
12 (table 1). We did not seek data
from five small trials that compared lengths of anti-
coagulation (total of 545 participants),
19-22 or from
two trials that did not routinely use objective testing
to confirm recurrent venous thromboembolism.
223
Definitions of clinical characteristics
We characterised the location of the initial venous
thromboembolism as pulmonary embolism, with or
without symptomatic deep vein thrombosis; proximal
deep vein thrombosis (involvement of the popliteal or
more proximal deep veins of the leg) without symp-
toms of pulmonary embolism; or isolated distal deep
veinthrombosis(noinvolvementoftheproximalveins
andnosymptomsofpulmonaryembolism).Indistinc-
tion to how they were reported in the original publica-
tions, patients with pulmonary embolism in
DOTAVK and DURAC 1 needed reclassification to
Table 1 |Design of original studies included in pooled analysis
Characteristic
ODAC
RCT*3
ODAC
cohort*3
DOTAVK
proximal*
DVT/PE9
DOTAVK
isolated
distal* DVT9 DURAC 14 LAFIT6 WODITDVT7
WODIT PE
TRF*8
WODIT PE
no TRF*8 SOFAST12
Study period 1987-
93
1987-93 1993-9 1993-9 1988-93 1994-7 1995-2000 1997-2000 1997-2000 1997-2001
Lengthoftreatmentbeforeenrolment(months) 1 1 0 0 0 3 3 3 3 1
Length of treatment after enrolment (months):
Shorter duration 0 2 3 1.5 1.5 0 0 0 0 0
Longer duration 2 2 6 3 6 24 9 3 9 2
Blinding Yes No No No No Yes No No No Yes
Follow-up after enrolment (months)†:
Mean 17.5 17.2 9.5 12.4 20.1 17.3 20.1 22.3 20.0 10.2
Maximum 24.0 24.0 14.3 16.4 24.0 24.0 24.0 24.0 24.0 22.3
PE=pulmonary embolism; RCT=randomised controlled trial; TRF=temporary risk factors.
*Predefined categories of patients with venous thromboembolism from same study are presented in separate columns.
†Analysis and data confined to follow-up after stopping vitamin K antagonist treatment for maximum of 24 months.
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4915 Pulmonary
embolism and proximal deep vein thrombosis were
diagnosed similarly in all studies. Isolated distal deep
vein thrombosis was diagnosed by venogram in
ODAC,
3 DURAC 1,
4 and SOFAST,
12 and predomi-
nantly by ultrasound in DOTAVK
9 (patients with iso-
lated distal deep vein thrombosis were not included in
LAFIT,
6 WODIT DVT,
7 and WODIT PE
8).
We categorised initial venous thromboembolism as
either provoked by a temporary risk factor or unpro-
voked(thatis,notprovokedbyatemporaryriskfactor,
butthepatientcouldhaveachronicmedicalcondition
other than cancer). The definition of a temporary risk
factordifferedacrossstudies,butinallstudiesthiscate-
gory included recent surgery, plaster cast immobilisa-
tionoftheleg,oradmissiontohospital.Allparticipants
had a first venous thromboembolism with symptoms,
exceptfor5% ofpatientsin LAFITwhohadhad a pre-
vious provoked thrombosis with symptoms,
6 9% in
ODAC who had a second thrombosis with
symptoms,
3and9%inSOFASTwhohadafirstasymp-
tomatic deep vein thrombosis detected by screening
after high risk surgery.
12
Length of treatment, follow-up, and diagnosis of recurrent
venous thromboembolism after treatment stopped
Lengths of treatment included 1.0, 1.5, 3, 6, 12, and
27monthsbeforeanticoagulationwasstoppedandfol-
low-up for this analysis started (table 1). All recur-
rences were confirmed by each study’s independent
outcome adjudication committee, and, except for a
small number of recurrent episodes of deep vein
thrombosisdetectedbyroutineimpedanceplethysmo-
graphy and confirmed by venography in ODAC,
3 all
recurrences were associated with symptoms. We lim-
ited follow-up to 24 months after anticoagulant treat-
ment was stopped for this analysis.
Statistical analysis
Wedividedlengthofanticoagulationbeforetreatment
was stopped into the four categories of 1.0 or 1.
5 months, 3 months, 6 months, and 12 or 27 months.
Follow-up for this analysis started the day that anti-
coagulant treatment stopped and was censored once
participants had a confirmed episode of recurrent
venous thromboembolism, died, stopped follow-up
in the original study, or had been followed for
24 months. We analysed time since stopping anti-
coagulant treatment as total follow-up (that is,
0-24 months), subdivided into 0-6 month and
7-24 month periods. We calculated rate of recurrence
asthenumberofeventsdividedbythetotalnumberof
patient years of follow-up (that is, events per 100
patient years).
We used Cox proportional hazard regression mod-
elling, stratified so as to preserve clustering of partici-
pants in the original studies, to assess the relation
between baseline factors and the rate of recurrent
venous thromboembolism.
15 Risk factors of interest
were length of anticoagulation before stopping
Table 2 |Characteristics of participants and rates of recurrent venous thromboembolism after stopping anticoagulant treatment in original studies. Values
are numbers (percentages) unless stated otherwise
Characteristic ODACRCT3
ODAC
cohort3
DOTAVK
proximal
DVT/PE9
DOTAVK
isolated
distalDVT9 DURAC 14 LAFIT6
WODIT
DVT7
WODIT PE
TRF8
WODIT PE
no TRF8 SOFAST12 All
No of participants 196 142 539 197 897 162 267 150 210 165 2925
Males 109 (56) 85 (60) 263 (49) 78 (40) 504 (56) 98 (60) 156 (58) 58 (39) 93 (44) 87 (53) 1531 (52)
Mean (SD) age (years) 61.7 (16.1) 60.7 (16.2) 61.6 (16.5) 50.2 (17.8) 60.9 (14.9) 59.2 (16.2) 64.4 (15.6) 55.7 (17.6) 67.0 (12.3) 55.7 (16.3) 60.5 (16.2)
Baseline
Isolated distal DVT 0 (0) 0 (0) 0 (0) 197 (100) 344 (38) 0 (0) 0 (0) 0 (0) 0 (0) 40 (24) 581 (20)
Proximal DVT 190 (97) 121 (85) 317 (59) 0 (0) 425 (47) 121 (75) 246 (92) 0 (0) 0 (0) 88 (53) 1508 (52)
Pulmonary embolism 6 (3) 21 (15) 222 (41) 0 (0) 128 (14) 41 (25) 21 (8) 150 (100) 210 (100) 37 (22) 836 (29)
No temporary provoking risk
factors present*
93 (47) 97 (68) 285 (53) 60 (30) 558 (62) 162 (100) 267 (100) 0 (0) 210 (100) 0 (0) 1732 (59)
Temporary provoking risk factors
present*
103 (53) 45 (32) 242 (45) 133 (68) 339 (38) 0 (0) 0 (0) 150 (100) 0 (0) 165 (100) 1177 (40)
Length of treatment
1 or 1.5 months 86 (44) 1 (1)† 11 (2)† 1 0 0( 5 1 ) 4 4 9( 5 0 ) 0( 0 ) 0( 0 ) 1( 1 ) † 0 (0) 89 (54) 737 (25)
3 months 105 (54) 139 (98) 244 (45) 82 (42) 12 (1)† 81 (50) 133 (50) 72 (48) 102 (49) 76 (46) 1046 (36)
6 months 4 (2)† 2( 1 ) † 245 (46) 3 (2)† 433 (48) 8 (5)† 2( 1 ) † 77 (51) 2 (1)† 0( 0 ) 7 7 6( 2 7 )
12 or 27 months 1 (1)† 0 (0) 29 (5)† 7( 4 ) † 0 (0) 73 (45) 132 (49) 0 (0) 106 (50) 0 (0) 348 (12)
Events
Episodes of VTE/patient years of
follow-up after stopping
treatment
13/284 20/203 36/415 4/196 144/1481 25/232 36/448 10/279 17/345 7/140 312/4023
Episodes of VTE per 100 patient
years after stopping treatment
(95% CI)
4.6
(2.7 to 7.9)
9.9
(6.4to15.3)
8.7
(6.3to12.0)
2.0
(0.8 to 5.4)
9.7
(8.3to11.4)
10.8
(7.3to15.9)
8.0
(5.8to11.1)
3.6
(1.9 to 6.7)
4.9
(3.1 to 7.9)
5.0
(2.4to10.5)
7.8
(6.9 to 8.7)
DVT=deep vein thrombosis; PE=pulmonary embolism; RCT=randomised controlled trial; TRF=temporary risk factors; VTE=venous thromboembolism.
*Patients with cancer not included in analysis.
†Patients received length of treatment different from that to which they were allocated.
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bolism, and whether the index venous thromboembo-
lism was provoked by a temporary risk factor. We
entered age and sex in the model to control for poten-
tial confounding effects. We assessed the association
between baseline variables and recurrent venous
thromboembolism for each of the 0-6 month and
7-24 month periods of follow-up in the Cox propor-
tional hazards modelling as a secondary analysis. We
derived adjusted cumulative probabilities of recurrent
venousthromboembolismfromthemultivariableCox
proportional hazard model and plotted them at the
mean value of all included covariates.
We assessed differences in the risk of recurrence
after different lengths of anticoagulation as follows.
We did a χ
2 test for heterogeneity between the four
categories of length of treatment. If heterogeneity was
statistically significant, we compared the risk of recur-
renceinthe1or1.5monthgroupwiththatinthethree
longer duration groups combined. We then did a test
for heterogeneity between the three longer treatment
groups,and,ifitwassignificant,wecomparedthethree
month group with the six and 12 or 27 month groups
combined. For these comparisons, we assumed that a
shorterdurationofanticoagulationcouldbeassociated
with a higher, but not a lower, risk of recurrence.
Statistical tests were two sided, and we considered P
values less than 0.05 to be statistically significant. We
used SAS version 9.1 for all analyses.
RESULTS
Participants’ characteristics
We included a total of 2925 participants with a mean
age of 60.5 years; 52% were male (table 2). Venous
thromboembolism was isolated distal deep vein
thrombosis in 20% of participants, proximal deep
vein thrombosis in 52%, and pulmonary embolism in
29% (table 2). Venous thromboembolism was
provoked by a temporary risk factor in 40% of partici-
pants and was unprovoked in 60%. Length of anti-
coagulant treatment was 1.0 or 1.5 months in 25% of
participants, three months in 36%, six months in 27%,
and 12 or 27 months in 12%.
Recurrent venous thromboembolism after anticoagulant
treatment stopped
Wehad4023patientyearsoffollow-up,corresponding
to a mean follow-up of 1.4 years per patient (table 2).
Three hundred and twelve episodes of recurrent
venous thromboembolism occurred during this per-
iod, corresponding to an overall rate of 7.8 (95% con-
fidence interval 6.9 to 8.7) per 100 patient years
(tables 2 and 3). The rate of recurrence was 12.2
(10.5 to 14.2) per 100 patient years in the first six
months after anticoagulant treatment was stopped
and5.5(4.7to6.5)per100patientyearsduringmonths
7-24 (table 3).
Length of anticoagulant treatment and risk of recurrence
In an analysis that included all participants (table 3),
the risk of recurrent venous thromboembolism during
the 24 monthperiod after anticoagulant treatment was
stopped differed among the four treatment duration
groups (P=0.02 for heterogeneity in the multivariable
model). The risk of recurrent venous thromboembo-
lism during the 24 month period was higher in the 1.0
or 1.5 month group compared with patients who were
treated for longer (hazard ratio 1.52, 95% confidence
interval1.14to2.02;P=0.004)(fig1).Theriskofrecur-
rence during the 24 month period was similar in the
three month, six month, and 12 or 27 month groups
(P=0.86 for heterogeneity), with no convincing evi-
dencethatitwashigherinthethreemonthgroupcom-
pared with those treated for six months or longer
(hazard ratio 1.19, 0.86 to 1.65; P=0.29). The higher
rate of recurrence in the 1.0 or 1.5 month group
Table 3 |Crude rates of recurrent VTE after stopping anticoagulant treatment according to location of initial VTE, length of treatment, and months of follow-
up after stopping treatment—all participants
Length of
treatment
(months)
Months after
stopping
treatment
Recurrent episodes of VTE per 100 patient years (95% CI) (events/patient years)
Pulmonary embolism Proximal DVT Isolated distal DVT All participants
1o r1 . 5
≤6 43.0 (25.9 to 71.4) (15/35) 21.9 (15.6 to 30.6) (34/155) 10.0 (5.9 to 16.9) (14/140) 19.1 (14.9 to 24.4) (63/330)
7-24 8.6 (3.9 to 19.1) (6/70) 7.2 (4.9 to 10.7) (25/345) 3.4 (1.9 to 6.4) (10/291) 5.8 (4.3 to 7.9) (41/706)
0-24 20.1 (13.1 to 30.8) (21/105) 11.8 (9.1 to 15.2) (59/500) 5.6 (3.7 to 8.3) (24/431) 10.0 (8.3 to 12.2) (104/1036)
3
≤6 10.8 (6.8 to 17.1) (18/167) 11.3 (7.9 to 16.0) (31/275) 4.2 (1.1 to 16.8) (2/48) 10.4 (7.9 to 13.7) (51/490)
7-24 2.9 (1.5 to 5.3) (10/347) 6.4 (4.5 to 9.0) (33/516) 2.2 (0.3 to 15.81) (1/45) 4.8 (3.6 to 6.5) (44/908)
0-24 5.4 (3.8 to 7.9) (28/514) 8.1 (6.3 to 10.3) (64/791) 3.2 (1.0 to 10.1) (3/93) 6.8 (5.6 to 8.3) (95/1398)
6
≤6 9.5 (5.3 to 17.2) (11/115) 10.2 (6.4 to 16.2) (18/176) 5.1 (1.9 to 13.5) (4/79) 8.9 (6.3 to 12.5) (33/370)
7-24 5.2 (2.9 to 9.3) (11/213) 8.1 (5.5 to 12.0) (26/319) 3.7 (1.8 to 7.3) (8/219) 6.0 (4.5 to 8.0) (45/751)
0-24 6.7 (4.4 to 10.2) (22/328) 8.9 (6.6 to 11.9) (44/495) 4.0 (2.3 to 7.1) (12/298) 7.0 (5.6 to 8.7) (78/1121)
12 or 27
≤6 11.4 (5.4 to 23.8) (7/62) 10.7 (5.6 to 20.5) (9/84) 0.0 (0/1.1) 10.9 (6.7 to 17.8) (16/147)
7-24 2.9 (1.1 to 7.8) (4/136) 8.1 (4.9 to 13.4) (15/185) NA 5.9 (3.8 to 9.3) (19/321)
0-24 5.6 (3.1 to 10.0) (11/198) 8.9 (6.0 to 13.3) (24/269) 0.0 (0/1.1) 7.5 (5.4 to 10.4) (35/468)
All
≤6 13.5 (10.2 to 17.7) (51/379) 13.3 (10.9 to 16.3) (92/691) 7.5 (4.8 to 11.6) (20/267) 12.2 (10.5 to 14.2) (163/1337)
7-24 4.0 (2.8 to 5.8) (31/766) 7.3 (6.0 to 8.8) (99/1365) 3.4 (2.2 to 5.4) (19/555) 5.5 (4.7 to 6.5) (149/2686)
0-24 7.2 (5.8 to 8.9) (82/1145) 9.3 (8.1 to 10.7) (191/2056) 4.7 (3.5 to 6.5) (39/822) 7.8 (6.9 to 8.7) (312/4023)
DVT=deep vein thrombosis; NA=not applicable; VTE=venous thromboembolism.
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months or longer was limited to the first six months
after anticoagulant treatment was stopped (hazard
ratio 2.12, 1.43 to 3.15; P<0.001), with no apparent
difference between these two groups during the
7-24 month follow-up period (1.05, 0.69 to 1.59;
P=0.83). Table 4 summarises the risk of recurrence in
the1.0or1.5monthgroup,sixmonthgroup,and12or
27 month group, compared with the three month
group.
In participants with provoked venous thrombo-
embolism(table 5),theriskofrecurrentvenousthrom-
boembolism during the 24 month period was not
statistically significantly different among the three
treatment duration groups (no participants were trea-
ted for 12 or 27 months) (P=0.21 for heterogeneity).
However, during the first six months after anti-
coagulant treatment was stopped, the risk of recurrent
venous thromboembolism differed significantly
among the three treatment groups (P=0.03 for hetero-
geneity). In the first six months, the risk of recurrent
venous thromboembolism was higher in the 1.0 or 1.
5 month group compared with patients treated for
three months or longer (hazard ratio 2.89, 1.25 to
6.69; P=0.013), with no suggestion that the risk of
recurrencewashigherinparticipantswhoweretreated
forthreemonthscomparedwithsixmonths(0.34,0.10
to 1.12).Therisk ofrecurrencewas similarin the three
treatment duration groups during the 7-24 month per-
iod after anticoagulant treatment was stopped (P=0.94
for heterogeneity), with no suggestion that the risk of
recurrence was higher in the 1.0 or 1.5 month group
comparedwiththosetreatedforlongerduringthisper-
iod (hazard ratio 0.97, 0.43 to 2.17; P=0.94).
In participants with unprovoked venous throm-
boembolism (table 6), the risk of recurrent venous
thromboembolism during the 24 month period dif-
fered among the four treatment duration groups
(P=0.009 for heterogeneity). The risk of recurrent
venousthromboembolismduringthe24monthperiod
was higher in the 1.0 or 1.5 month group compared
withpatientstreatedforthreemonthsorlonger(hazard
ratio 1.52, 1.09 to 2.12; P=0.014). This difference
mainly occurred in the first six months after anti-
coagulant treatment was stopped (hazard ratio 2.00,
1.27 to 3.17; P=0.003), with little suggestion that the
risk of recurrence during the 7-24 month period was
higher in the 1.0 or 1.5 month group compared with
thosetreatedforlonger(1.10,0.67to1.80;P=0.70).We
found a trend for a higher risk of recurrent venous
thromboembolism during the 24 month period in the
threemonthgroupcomparedwiththosetreatedforsix
months or longer (hazard ratio 1.39, 0.96 to 2.01;
P=0.08). During the first six months of follow-up, this
difference was statistically significant (1.70, 1.02 to
2.82; P=0.041).
Location of initial episode of venous thromboembolism and
risk of recurrence
Therisk ofrecurrence duringthe24monthperiodwas
lower in participants with isolated distal deep vein
thrombosis than in those with proximal deep vein
thrombosis (hazard ratio 0.49, 0.34 to 0.71; P<0.001)
or pulmonary embolism (0.41, 0.27 to 0.63; P<0.001)
(table 3andfig2).Duringthe24monthperiod,therisk
of recurrence was similar in participants with pulmon-
ary embolism and proximal deep vein thrombosis
(hazard ratio 1.19, 0.87 to 1.63; P=0.27). However,
the risk of recurrence in participants with pulmonary
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Fig 1 | Cumulative probability (top) and rate (bottom) of
recurrent venous thromboembolism (VTE) after stopping
treatment according to initial length of treatment (adjusted for
age, sex, study, location of initial VTE, and presence of
temporary risk factor. Rate of recurrent VTE calculated for 0-
0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, 12-18, and 18-24 month
intervals of follow-up
Table 4 |Predictors of recurrent venous thromboembolism
after stopping anticoagulant treatment, from multivariable
Cox regression analysis*
Variable Hazard ratio (95% CI) P value
Length of treatment:
1o r1 . 5m o n t h s † 1.28 (0.82 to 2.01) 0.28
3 months 1.0 (reference)
6 months 0.80 (0.51 to 1.25) 0.33
12 or 27 months 0.88 (0.57 to 1.36) 0.56
Location of initial VTE:
Proximal DVT 1.0 (reference)
Pulmonary embolism† 1.19 (0.87 to 1.63) 0.27
Isolated distal DVT 0.49 (0.34 to 0.71) <0.001
Provoking risk factors v
unprovoked
0.55 (0.41 to 0.74) <0.001
DVT=deep vein thrombosis; VTE=venous thromboembolism.
*Model included age, sex, and trial as potential confounders.
†In a separate multivariable model that distinguished between 0-6 and
7-24 month intervals of follow-up, a statistically significant difference
between these two time intervals was found for this variable (see text).
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bosis differed (P=0.012 for interaction) between the
0-6 month (hazard ratio 1.65, 1.12 to 2.43) and
7-24 month (0.74, 0.43 to 1.25) periods (tables 3 and
4).Additionalanalysessuggestedthatthehigherriskof
recurrence during the first six months after stopping
treatment in participants with pulmonary embolism
mainly occurred in participants who were treated for
only 1.0 or 1.5 months (hazard ratio 2.03, 1.12 to
3.69), with less evidence of a difference in those who
were treated for three months or longer (1.45, 0.89 to
2.39) (table 3). Other than for this observation, we
found no evidence that the location of venous throm-
boembolism altered the relative risk of recurrence that
was associated with different lengths of anticoagulant
treatment.
Provoked versus unprovoked venous thromboembolism
and risk of recurrence
The risk of recurrence in participants with an initial
event that was provoked by a temporary risk factor
was about half of that in participants with unprovoked
venous thromboembolism (hazard ratio 0.55, 0.41 to
0.74; P=0.0001) (fig 3 and table 4), with no evidence
that this effect was modified by the length of anti-
coagulant treatment or the location of venous throm-
boembolism. The lower risk of recurrence in
participants with an initial event provoked by a tem-
porary risk factor compared with those with unpro-
voked venous thromboembolism was similar in the
first six month period (hazard ratio 0.49, 0.32 to 0.75;
P=0.009) and in the 7-24 month period (0.62, 0.41 to
0.94; P=0.024).
Isolated distal deep vein thrombosis provoked by a
temporary risk factor was associated with a low abso-
lute risk of recurrence after stopping anticoagulant
treatment (2.0 (95% confidence interval 1.0 to 3.8)
per100patientyearsforallsuchparticipants)(table 5).
We found no suggestion that this subgroup of partici-
pants had a higher risk of recurrence if they were trea-
ted for 1.0 or 1.5 months compared with three months
or longer (hazard ratio 0.36, 0.09 to 1.54; P=0.17),
although only nine recurrent episodes of venous
thromboembolism contributed to this comparison. In
contrast, participants with unprovoked isolated distal
deepveinthrombosis(table 6)hadahighabsoluterisk
of recurrence (8.1 (5.7 to 11.6) per 100 patient years),
and the risk of recurrence was higher in such partici-
pantswhoweretreatedfor1.0or1.5monthscompared
with a longer duration of treatment (hazard ratio 2.30,
1.05 to 5.03; P=0.04).
DISCUSSION
This analysis found that three months of anticoagulant
treatment resulted in a similar risk of recurrence after
treatment was stopped to a longer duration of treat-
ment and that shortening treatment to 1.0 or 1.
5monthsdoubledrecurrencerates.Subgroupanalyses
suggestedtwopossibleexceptionstotheseoverallfind-
ings. Firstly, patients with isolated distal deep vein
thrombosis provoked by a temporary risk factor did
not seem to have a higher risk of recurrence if they
were treated for only 1.0 or 1.5 months. Secondly,
patients with unprovoked venous thromboembolism
seemed to have a lower risk of recurrence if they
were treated for six months or longer compared with
three months. When a shorter course of treatment was
associated with a higher rate of recurrence, this
increasewasconfinedtothe first six monthsafterstop-
ping treatment.
The analysis also confirmed, and more precisely
defined,thatthe riskofrecurrenceafterstoppingtreat-
ment is about double when venous thromboembolism
is unprovoked compared with if it is provoked by a
temporary risk factor
2-4918; that the risk is about half
afteranisolateddistaldeepveinthrombosiscompared
Table 5 |Crude rates of recurrent VTE after stopping anticoagulant treatment according to location of initial VTE, length of treatment, and months of follow-
up after stopping—patients with provoked VTE
Length of
treatment
(months)
Months after
stopping
treatment
Recurrent episodes of VTE per 100 patient years (95% CI) (events/patient years)
Pulmonary embolism Proximal DVT Isolated distal DVT All participants
1o r1 . 5
≤6 21.7 (8.1 to 57.8) (4/18) 16.7 (9.7 to 28.7) (13/78) 1.2 (0.2 to 8.5) (1/84) 10.0 (6.3 to 15.9) (18/180)
7-24 3.0 (0.4 to 21.0) (1/34) 5.6 (2.9 to 10.7) (9/162) 1.3 (0.3 to 5.0) (2/159) 3.4 (1.9 to 6.0) (12/355)
0-24 9.6 (4.0 to 23.0) (5/52) 9.2 (6.0 to 13.9) (22/240) 1.2 (0.4 to 3.8)(3/243) 5.6 (3.9 to 8.0) (30/535)
3
≤6 5.5 (2.1 to 14.7) (4/72) 0.0 (0/92) 2.9 (0.4 to 20.7) (1/34) 2.5 (1.0 to 6.0) (5/198)
7-24 1.4 (0.4 to 5.8) (2/139) 5.0 (2.4 to 10.4) (7/141) 0.0 (0/32) 2.9 (1.5 to 5.6) (9/312)
0-24 2.8 (1.3 to 6.3) (6/211) 3.0 (1.4 to 6.3) (7/233) 1.5 (0.2 to 10.8) (1/66) 2.7 (1.6 to 4.6) (14/510)
6
≤6 7.9 (3.3 to 18.9) (5/64) 7.2 (3.0 to 17.2) (5/70) 5.3 (1.3 to 21.4) (2/37) 7.0 (4.0 to 12.4) (12/171)
7-24 3.7 (1.5 to 8.8) (5/136) 6.4 (3.1 to 13.5) (7/109) 2.9 (0.9 to 8.8) (3/105) 4.3 (2.6 to 7.1) (15/350)
0-24 5.0 (2.7 to 9.3) (10/200) 6.7 (3.8 to 11.8) (12/179) 3.5 (1.5 to 8.4) (5/142) 5.2 (3.6 to 7.6) (27/521)
12 or 27
≤6 0.0 (0/2) 0.0 0.0 (0/1) 0.0 (0/2)
7-24 NA NA NA NA
0-24 0.0 (0/2) 0.0 0.0 (0/1) 0.0 (0/2)
All
≤6 8.3 (4.8 to 14.4) (13/156) 7.5 (4.7 to 11.9) (18/240) 2.6 (1.0 to 6.8) (4/156) 6.3 (4.6 to 8.8) (35/552)
7-24 2.6 (1.3 to 5.2) (8/309) 5.6 (3.7 to 8.4) (23/411) 1.7 (0.7 to 4.1) (5/296) 3.5 (2.6 to 4.9) (36/1016)
0-24 4.5 (2.9 to 6.9) (21/465) 6.3 (4.6 to 8.5) (41/651) 2.0 (1.0 to 3.8) (9/452) 4.5 (3.6 to 5.7) (71/1568)
DVT=deep vein thrombosis; NA=not applicable; VTE=venous thromboembolism.
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pulmonary embolism
4916; and that the rate of recur-
rence during the first six months of follow-up is about
double the rate during the next 18 months.
24 Patients
with venous thromboembolism and cancer, who gen-
erally remain on anticoagulant treatment long term
because they have a high risk of recurrence, were not
included in the analysis.
1
Strengths and limitations
Strengths of our analysis that increase the precision
and validity of its findings are that we included data
froma largenumberofparticipants,baselinevariables
were recorded at enrolment rather than retrospec-
tively, the time of stopping anticoagulant treatment
was well documented, participants were followed
prospectively with very few unexplained losses to
follow-up, and recurrent thrombosis was accurately
diagnosed by adjudication committees. Limitations
are that participants were not consecutive patients
with venous thromboembolism, the precision of esti-
mates among subgroups is still limited, only 12% of
participants were in the 12 or 27 month group (all
had unprovoked proximal deep vein thrombosis or
pulmonary embolism), we were unable to assess the
influence of thrombophilic states and other laboratory
variables on risk of recurrence, and inferences about
the influence of different lengths of treatment on risk
of recurrence are based on comparisons across studies
aswellaswithinstudies.Inaddition,wewereunableto
differentiate between patients who had venous throm-
boembolismprovokedbyminorandmajortemporary
risk factors, a distinction that has been shown to influ-
ence the risk of recurrence, with a particularly low risk
of recurrence if thrombosis was associated with recent
surgery.
25 Another potential limitation is that the ana-
lysis included a non-randomised cohort of patients
with proximal deep vein thrombosis who were treated
for three months because they had abnormal impe-
dance plethysmography after one month of treatment,
and some of the recurrent episodes of deep vein
Table 6 Crude rates of recurrent VTE after stopping anticoagulant treatment according to location of initial VTE, length of treatment, and months of follow-
up after stopping—participants with unprovoked VTE
Length of
treatment
(months)
Months after
stopping
treatment
Recurrent episodes of VTE per 100 patient years (95% CI) (events/patient years)
Pulmonary embolism Proximal DVT Isolated distal DVT All participants
1o r1 . 5
≤6 67.0 (37.1 to 120.9) (11/16) 27.1 (17.6 to 41.5) (21/78) 23.0 (13.3 to 39.6) (13/57) 29.9 (22.3 to 40.0) (45/151)
7-24 13.9 (5.8 to 33.5) (5/36) 8.7 (5.4 to 14.3) (16/183) 6.1 (3.0 to 12.2) (8/131) 8.3 (5.8 to 11.9) (29/350)
0-24 30.6 (18.7 to 49.9) (16/53) 14.2 (10.3 to 19.6) (37/261) 11.2 (7.3 to 17.1) (21/188) 14.8 (11.8 to 18.6) (74/501)
3
≤6 14.9 (8.8 to 25.2) (14/94) 17.0 (11.9 to 24.1) (31/183) 7.9 (1.1 to 56.0) (1/13) 15.9 (11.9 to 21.2) (46/289)
7-24 3.8 (1.9 to 7.7) (8/208) 6.9 (4.7 to 10.2) (26/375) 7.9 (1.1 to 56.3) (1/12) 5.9 (4.2 to 8.2) (35/596)
0-24 7.3 (4.8 to 11.1) (22/302) 10.2 (7.9 to 13.3) (57/558) 7.9 (2.0 to 31.6) (2/25) 9.2 (7.4 to 11.4) (81/885)
6
≤6 11.6 (5.2 to 25.9) (6/52) 12.4 (7.2 to 21.4) (13/104) 4.8 (1.2 to 19.3) (2/41) 10.6 (6.9 to 16.3) (21/197)
7-24 7.9 (3.5 to 17.5) (6/76) 9.1 (5.8 to 14.2) (19/210) 4.4 (1.8 to 10.6) (5/114) 7.5 (5.2 to 10.7) (30/400)
0-24 9.4 (5.3 to 16.5) (12/128) 10.2 (7.2 to 14.4) (32/314) 4.5 (2.2 to 9.5) (7/155) 8.5 (6.5 to 11.2) (51/597)
12 or 27
≤6 11.6 (5.5 to 24.4) (7/60) 10.7 (5.6 to 20.6) (9/84) NA 11.1 (6.8 to 18.1) (16/144)
7-24 2.9 (1.1 to 7.8) (4/136) 8.1 (4.9 to 13.4) (15/185) NA 5.9 (3.8 to 9.3) (19/321)
0-24 5.6 (3.1 to 10.1) (11/196) 8.9 (6.0 to 13.3) (24/269) NA 7.5 (5.4 to 10.5) (35/465)
All
≤6 17.1 (12.4 to 23.5) (38/222) 16.5 (13.1 to 20.7) (74/449) 14.4 (8.8 to 23.5) (16/111) 16.4 (13.8 to 19.5) (128/782)
7-24 5.0 (3.3 to 7.6) (23/457) 8.0 (6.4 to 10.0) (76/952) 5.4 (3.2 to 9.2) (14/258) 6.8 (5.6 to 8.2) (113/1667)
0-24 9.0 (7.0 to 11.6) (61/679) 10.7 (9.1 to 12.6) (150/1401) 8.1 (5.7 to 11.6) (30/369) 9.8 (8.7 to 11.2) (241/2449)
DVT=deep vein thrombosis; NA=not applicable; VTE=venous thromboembolism.
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Fig 2 | Cumulative probability (top) and rate (bottom) of
recurrent venous thromboembolism (VTE) after stopping
treatment according to whether VTE was pulmonary
embolism, proximal deep vein thrombosis, or isolated distal
deep vein thrombosis (adjusted for age, sex, study, length of
treatment before stopping anticoagulant, and presence of
temporary risk factor). Rate of recurrent VTE calculated for 0-
0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, 12-18, and 18-24 month
intervals of follow-up
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of this study were detected by routine impedance
plethysmography in the absence of new symptoms.
3
However, a sensitivity analysis that excluded this
study resulted in similar findings (data not shown).
Clinical implications and conclusions
The clinical implications of our findings are that if
patients with venous thromboembolism do not have
an indication for indefinite anticoagulant treatment
they generally should stop treatment at three months.
As patients with a provoked isolated distal deep vein
thrombosiswhoweretreatedfor1.0or1.5monthshad
a low risk of recurrence, and as extending treatment to
three months did not seem to further lower this risk,
our results suggest that the risk of recurrence will not
be excessive if such patients need to stop anti-
coagulants before they have completed three months
oftreatment.Patientswithunprovokedproximaldeep
vein thrombosis or pulmonary embolism had a high
risk of recurrence whenever they stopped treatment;
consistentwiththisobservation,severalstudiessuggest
that these patients will often benefit from indefinite
anticoagulant treatment.
12627 If patients with unpro-
voked proximal deep vein thrombosis or pulmonary
embolismarenottreatedindefinitely,thisanalysissug-
gests that their risk of recurrence may be higher if they
are treated for three months rather than six months
(recurrent venous thromboembolism during the six
months after stopping treatment in participants with
unprovoked proximal deep vein thrombosis or pul-
monary embolism who were treated for three months
comparedwithsixmonthsorlonger:hazardratio1.57,
95% confidence interval 0.94 to 2.61; P=0.08). How-
ever, as the increase in recurrent venous thrombo-
embolism in the three month group was of borderline
statistical significance, as we found no suggestion of a
comparable increase in participants with provoked
proximal deep vein thrombosis or pulmonary embo-
lism who were treated for three months rather than six
months, and as this finding was one of many subgroup
analyses, we cannot be certain that this was a true
increase. Although extending treatment from three
months to six months in such patients may reduce the
subsequent risk of recurrent venous thromboembo-
lism,thispotentialbenefitneedstobebalancedagainst
a higher risk of bleeding with, and the greater cost and
inconvenience of, the longer duration of treatment.
1
Elevated D-dimer concentrations during or after anti-
coagulanttreatment seemto be a valuable predictorof
recurrence in patients with unprovoked venous
thromboembolism.
28-30 This analysis was unable to
assess if D-dimer or other laboratory variables were
predictors of recurrence. If such factors improve iden-
tification of the subgroup of patients with unprovoked
venousthromboembolismwhocanstopanticoagulant
treatment because they have a low risk of recurrence,
theresultsofthisanalysissuggestthattreatmentcanbe
stopped after three months of anticoagulation.
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Fig 3 | Cumulative probability (top) and rate (bottom) of
recurrent venous thromboembolism (VTE) after stopping
treatment according to whether VTE was provoked by a
temporary risk factor or was unprovoked (adjusted for age,
sex, study, length of treatment before stopping anticoagulant,
and location of initial VTE). Rate of recurrent VTE calculated for
0-0.5, 0.5-1, 1-2, 2-4, 4-8, 8-12, 12-18, and 18-24 month
intervals of follow-up
WHAT IS ALREADY KNOWN ON THIS TOPIC
In general, venous thromboembolism should be treated for at least three months, and the
risk of recurrence increases when anticoagulant treatment is stopped
Whether treatment of venous thromboembolism for longer than three months reduces the
risk of recurrence when anticoagulation is ultimately stopped is uncertain
Whether the minimum length of anticoagulant treatment should be influenced by the initial
presentation of venous thromboembolism is also uncertain
WHAT THIS STUDY ADDS
If the risk of recurrent venous thromboembolism is not high enough to justify indefinite
anticoagulation, treatment can be stopped after three months in most patients
The risk of recurrence after stopping anticoagulants is doubled if venous thromboembolism
was a proximal deep vein thrombosis or pulmonary embolism compared with an isolated
distal deep vein thrombosis
The risk is also doubled if thrombosis was unprovoked rather than provoked by a temporary
risk factor, and the influence of these two factors on the risk of recurrence is additive
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